GlassScriptPhysician profile
Timothy A Gong
NPI 1992023188
$107,107.08
in general payments reported to CMS, 2019-2025
21 companies · $7,226 in 2025
The $7,226 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $22K · 2021: $43K · 2022: $7,254 · 2023: $21K · 2024: $5,593 · 2025: $7,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $7,244 · Food and Beverage: $4,921 · Travel and Lodging: $2,377 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,000.00 |
| Consulting Fee | $7,243.75 |
| Food and Beverage | $4,921.16 |
| Travel and Lodging | $2,377.46 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $85,084.02 | 2020-2024 | Farxiga |
| Cvrx, INC. | $8,902.80 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $5,456.72 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Medtronic Vascular, INC. | $4,960.85 | 2019-2020 | |
| Abiomed | $1,019.27 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $769.16 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.05 | 2024-2025 | Camzyos, Eliquis |
| Livanova USA, INC. | $142.46 | 2023 | Protekduo |
| Boston Scientific Corporation | $137.44 | 2024 | Avvigo Guidance System |
| Pfizer INC. | $130.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $93.26 | 2020-2024 | Verquvo |
| Ancora Heart, INC. | $56.01 | 2025 | Accucinch |
| Scpharmaceuticals INC. | $49.51 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.41 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $19.66 | 2020 | |
| Novo Nordisk INC | $18.28 | 2021 | |
| La Jolla Pharmaceutical Company | $17.10 | 2022 | |
| Lantheus Medical Imaging, INC. | $15.78 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.68 | 2023 | Lifevest |
| Abbvie INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.